Thirty-nine patients who were positive for both Aβ and phosphorylated tau biomarkers were classified as “A+/T+”, while 56 patients who were either negative for both markers or positive for only one were classified as “isolated Aβ/non-AD.” Here, MAPT is linked to Alzheimer disease.